NEUROSENSE THERAPEUTICS LTD (NRSN)
IL0011809592 - Common Stock
NEUROSENSE THERAPEUTICS LTD
NASDAQ:NRSN (12/23/2024, 8:22:20 PM)
After market: 1.29 +0.04 (+3.2%)1.25
-0.11 (-8.09%)
Company Profile
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Company Info
NEUROSENSE THERAPEUTICS LTD
11 Hamenofim St., Building B
Herzliya
P: 97299531142
Employees: 18
Website: https://www.neurosense-tx.com/
NRSN News
11 hours ago - ChartmillWhich stocks are gapping on Monday?Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
12 hours ago - NeurosenseNeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
5 days ago - NeurosenseNeuroSense Provides Business Update and Third Quarter 2024 Financial Results/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe...
12 days ago - NeurosenseNeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
20 days ago - NeurosenseNeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
22 days ago - NeurosenseNeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
NRSN Twits
Here you can normally see the latest stock twits on NRSN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
